| Organization |
year |
Recommandations |
| European Association
of Urology |
2011 |
1-Widespread screening not appropriate.
2-Offer early detection to well-informed men.
3-Baseline PSA at age 40 yr has been suggested on which subsequent screening interval may be based.
4-Screening interval of 8 yr might be enough in men with initial PSA < 1 ng/ml.
5-Further PSA testing is not necessary in men >75 yr of age and a baseline PSA < 3 ng/ml |
American Urological
Association |
2009 |
1-Offer early detection to asymptomatic men > 40 yr of age who wish to be screened and who have an estimated life expectancy >10 yr.
2-Screening intervals should be based on this baseline PSA level.
3-A ssess the individual patient’s health status to determine the appropriateness of PSA testing at any given age. |
American Cancer
Society |
2010 |
1-Asymptomatic men who have at least a 10-yr life expectancy should have an opportunity to make an informed decision with their health care provider about whether to be screened.
2-Men at average risk should receive this information beginning at 50 yr of age.
3-African American men and men who have a first-degree relative diagnosed with PCa < 65 yr should receive this information beginning at age 45 yr.
4-Men with multiple family members diagnosed with PCa < 65 yr should receive this information beginning at age 40 yr. |
National Comprehensive
Cancer Network |
2010 |
1-Offer baseline digital rectal examination and PSA testing at age 40 after providing counseling on the pros and cons of early detection.
2-If African American, if there is a family history of PCa, or if the PSA level is >1.0 ng/ml, repeat annually.
3-Otherwise, repeat at age 45 and annually starting at 50. Screening in men >75 yr should be considered individually. |